Description
Role of Biomarkers in Cancer Diagnosis and Therapeutics offers a thorough exploration of the critical roles biomarkers play in cancer detection, diagnosis, monitoring, and therapy. Sections focus on established and emerging biomarkers like PSA and CEA, detailing their biochemical characteristics and clinical relevance, and examining metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic potential. The final part pf the book discusses innovative strategies targeting cell cycle checkpoints and DNA repair mechanisms, including synthetic lethality through PARP inhibitors. This essential resource provides researchers and clinicians with insights into novel metabolic targets and cutting-edge treatment strategies.By addressing current applications and future challenges, including the integration of AI and multi-omics approaches, the book equips readers with actionable knowledge to advance personalized cancer care and navigate the dynamic landscape of oncology.- Provides an in-depth analysis of both established and emerging cancer biomarkers, detailing their biochemical characteristics, clinical relevance, and diagnostic potential across various malignancies- Explores critical metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic implications, thereby offering insights into novel targets for cancer treatment- Discusses cutting-edge approaches that target cell cycle checkpoints and DNA repair mechanisms, including the concept of synthetic lethality, thus equipping readers with advanced knowledge for personalized cancer therapies
Table of Contents
I. Biomarkers in Cancer Diagnosis and Treatment1. Prostate-Specific Antigen (PSA)2. Carcinoembryonic Antigen (CEA)3. Tissue Polypeptide-Specific Antigen (TPS) CA72-44. Carbohydrate Antigen 19-9 (CA19-9)5. Carbohydrate Antigen 125 (CA-125)6. Carbohydrate Antigen 72-4 (CA72-4)7. Aminopeptidase N8. Alkaline Phosphatase9. CD26/Dipeptidyl Peptidase (DPP)410. Genetic Biomarkers in Cancer11. Immunology Biomarkers in Cancer12. Microbiome Biomarkers in Cancer13. Glycobiology Biomarkers in Cancer14. Epigenetic Biomarkers in CancerII. Metabolic Targets and Cancer Therapeutics15. Introduction to Metabolic Targets and Autophagy16. Glucose Metabolism – Hexokinase-2 (HK2), Lactate Dehydrogenase A (LDHA), Pyruvate Kinase M2 Isoform (PKM2), Pyruvate Dehydrogenase (PDK), Glucose Transporter, Enolase 1 (ENO1), and Monocarboxylate Transporter (MCT1)17. Nucleic Acid Metabolism – Folate Cycle, Nucleotide Incorporation (DNA Polymerase/Ribonucleotide Reductase (RNR)), Deoxynucleotide Synthesis (RNR), and Thymidine Synthesis (TYMS)18. Amino Acid Metabolism – Arginine and Asparagine, Serine/Threonine Protein Kinase (Glycogen Synthase Kinase-3 (GSK-3))19. Glucose and Amino Acid Metabolism - Isocitrate Dehydrogenase-1 (IDH-1)20. Glucose, Nucleic Acid, Fatty Acid, and Amino Acid Metabolism – Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)III. Miscellaneous Cancer Therapeutic Approaches21. Targeting DNA Repair Pathways – O-6-Methylguanine-DNA Methyltransferase (MGMT), Base Excision Repair, Double Strand Breaks Repair, and mtDNA Repair22. Cell Cycle Inhibition – Cyclin-Dependent Kinases (CDKs), and G1 Checkpoint23. Topoisomerase-Induced DNA Damage and Therapeutic Potential24. Polo-like Kinase 4 (PLK4) Inhibitors in Cancer Therapy25. Synthetic Lethality by Poly (ADP-Ribose) Polymerase Inhibitors26. Innovative Therapeutic Approaches
